Invesco Private Capital’s Xenon Pharmaceuticals XENE Stock Holding History

Invesco Private Capital’s Portfolio XENE Stock Details XENE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-79,539	Closed	-$808K	–	6
2019 Q1	$808K	Sell	79,539 -50,000	-39%	-$424K	0.22%	4
2018 Q4	$817K	Hold	129,539	–	–	0.34%	4
2018 Q3	$1.71M	Sell	129,539 -119,284	-48%	-$1.38M	0.63%	3
2018 Q2	$2.29M	Sell	248,823 -93,061	-27%	-$578K	0.81%	3
2018 Q1	$1.68M	Hold	341,884	–	–	0.65%	2
2017 Q4	$968K	Sell	341,884 -33,900	-9%	-$92.2K	0.3%	3
2017 Q3	$1.11M	Hold	375,784	–	–	0.31%	4
2017 Q2	$1.18M	Sell	375,784 -5,000	-1%	-$19.5K	0.4%	4
2017 Q1	$1.52M	Sell	380,784 -19,893	-5%	-$156K	0.29%	5
2016 Q4	$3.08M	Sell	400,677 -11,802	-3%	-$94.8K	0.67%	6
2016 Q3	$3.34M	Sell	412,479 -23,905	-5%	-$185K	0.87%	5
2016 Q2	$2.58M	Hold	436,384	–	–	0.54%	5
2016 Q1	$3.05M	Hold	436,384	–	–	0.54%	5
2015 Q4	$3.51M	Sell	436,384 -8,271	-2%	-$70.9K	0.67%	5
2015 Q3	$3.67M	Hold	444,655	–	–	0.76%	6
2015 Q2	$5.13M	Hold	444,655	–	–	0.65%	7
2015 Q1	$7.63M	Hold	444,655	–	–	0.95%	6
2014 Q4	$8.78M	Buy	+444,655	New	+$6.53M	1.01%	6

Other funds holding XENE

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $7.48B AUM 104.76% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

ACM

Aquilo Capital Management San Francisco, California $55.8M AUM 41.76% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

ACP

Acuta Capital Partners Redwood City, California $143M AUM 773.18% 1-Year Est. Return

Invesco Private Capital's XENE Position: Q2 2019 in Review

Invesco Private Capital sold out of Xenon Pharmaceuticals (XENE) in Q2 2019, closing a stake of 79,539 shares — an estimated $808K sold.

Invesco Private Capital first reported a position in XENE in Q4 2014 and held it in 18 quarters. The position peaked at $8.78M in Q4 2014. 60 funds tracked by Wall St. Rank hold XENE as of Q2 2019.

Invesco Private Capital reported no remaining Xenon Pharmaceuticals position as of Q2 2019 after selling out during the quarter.
Invesco Private Capital sold 79,539 Xenon Pharmaceuticals shares in Q2 2019, an estimated $808K.
Invesco Private Capital first reported a position in Xenon Pharmaceuticals in Q4 2014 and held it in 18 quarters.
Invesco Private Capital's Xenon Pharmaceuticals position peaked at $8.78M in Q4 2014.
60 funds tracked by Wall St. Rank held Xenon Pharmaceuticals as of Q2 2019.

Based on Invesco Private Capital's 13F filing for Q2 2019, filed 14 Aug 2019.